4.6 Article

Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial

期刊

PLOS ONE
卷 10, 期 3, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0118393

关键词

-

资金

  1. TI Food and Nutrition, a public-private partnership on precompetitive research in food and nutrition

向作者/读者索取更多资源

Background In vitro and animal studies have shown positive effects of resveratrol on lipid and lipoprotein metabolism, but human studies specifically designed to examine these effects are lacking. Objective The primary outcome parameter of this study in overweight and slightly obese subjects was the effect of resveratrol on apoA-I concentrations. Secondary outcome parameters were effects on other markers of lipid and lipoprotein metabolism, glucose metabolism, and markers for inflammation and endothelial function. Design This randomized, placebo-controlled crossover study was conducted in 45 overweight and slightly obese men (n = 25) and women (n = 20) with a mean age of 61 +/- 7 years. Subjects received in random order resveratrol (150 mg per day) or placebo capsules for 4 weeks, separated by a 4-week wash-out period. Fasting blood samples were collected at baseline and at the end of each intervention period. Results Compliance was excellent as indicated by capsule count and changes in resveratrol and dihydroresveratrol concentrations. No difference between resveratrol and placebo was found in any of the fasting serum or plasma metabolic risk markers (mean +/- SD for differences between day 28 values of resveratrol vs. placebo: apoA-I; 0.00 +/- 0.12 g/L (P = 0.791), apoB100; -0.01 +/- 0.11 g/L (P = 0.545), HDL cholesterol; 0.00 +/- 0.09 mmol/L P = 0.721), LDL cholesterol -0.03 +/- 0.57 mmol/L (P = 0.718), triacylglycerol; 0.10 +/- 0.54 mmol/L (P = 0.687), glucose; -0.08 +/- 0.28 mmol/L (P = 0.064), insulin; -0.3 +/- 2.5 mU/L (P = 0.516)). Also, no effects on plasma markers for inflammation and endothelial function were observed. No adverse events related to resveratrol intake were observed. Conclusion 150 mg of daily resveratrol intake for 4 weeks does not change metabolic risk markers related to cardiovascular health in overweight and slightly obese men and women. Effects on glucose metabolism warrant further study.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据